Anthracycline combination therapy for children with nephroblastoma
Treatments studied
Part of Cancer, Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of anthracycline drugs, including doxorubicin, for children with nephroblastoma (a type of kidney cancer). The goal is to see if this treatment is safe and effective for children who need this chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 6 months and 14 years old.
- Your child must have a confirmed diagnosis of nephroblastoma (a kidney tumor).
- Your child must not have smoked (this is usually not an issue for children).
- Your child must be able to follow the treatment plan and attend study visits.
- Your child must not have other serious heart, liver, kidney, or blood diseases.
- Your child must not have had certain chemotherapy or heart-damaging treatments in the past 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatment combinations—liposomal doxorubicin plus irinotecan versus a different chemotherapy plan—in children and teens whose rhabdomyosarcoma came back or did not respond. It aims to see which option works better and is safer for children who have had prior cancer treatment.
This trial tests a combination of four drugs (liposomal irinotecan, vincristine, temozolomide, and anlotinib) for children and teens whose solid tumors have come back or haven't responded to standard treatment. The goal is to see if this drug mix can shrink or control the tumors.
This trial tests a combination of four drugs (chidamide, dinutuximab beta, irinotecan, and temozolomide) for children whose neuroblastoma has returned or isn't responding to standard treatment. It aims to see if this mix can shrink the tumor or stop it from growing.
This trial tests a treatment plan for children with newly diagnosed acute lymphoblastic leukemia (ALL) that is considered standard-risk. It aims to see if the treatment is effective and safe.
This trial studies a treatment approach for children and teens newly diagnosed with lymphoblastic lymphoma. It may help doctors choose therapies based on genetic risk information from lab testing done on tumor samples.
This trial tests a combination of three chemotherapy drugs (irinotecan, temozolomide, and vincristine) in children and teens whose solid tumors have come back or stopped responding to standard treatment. The goal is to see if this combination can help shrink or control the tumors.
Hear when a new 0.5-14 Year Old Children With Nephroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.